Recrutamento encerrado
FASE
Número Europeu 2020-000633-40
PAPILLON - 61186372NSC3001
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Detalhes
Destaques